Here are the 424B prospectus supplements from Estrella Immunopharma, Inc. (ESLA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ESLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESLA filings page.
Estrella Immunopharma, Inc. has registered up to 9,236,141 shares of common stock for resale by existing selling stockholders. These resale shares, including warrant shares and true-up and reset shares from prior financings, equal about 22.0% of outstanding common stock as of January 11, 2026, and Estrella will receive no proceeds from their sale.
The company is a clinical-stage T‑cell therapy developer, led by CD19‑directed candidate EB103, which has early Phase I data in B‑cell lymphomas but remains in development. Estrella reported net losses of $12.5 million for the nine months ended September 30, 2025 and had an accumulated deficit of about $36.4 million, with only $1.6 million in cash and cash equivalents as of that date, leading to substantial doubt about its ability to continue as a going concern.
Control is concentrated: Eureka Therapeutics, Inc. holds roughly 60.1% of outstanding common stock and voting power, making Estrella a Nasdaq “controlled company.” The prospectus highlights high risk from significant ongoing losses, the need for substantial additional funding, dependence on Eureka for manufacturing and key intellectual property, and the potential for resale-related stock overhang that could pressure the share price.